Allogene Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0197701065

SecurityALLO / Allogene Therapeutics, Inc.
InstitutionCitadel Advisors Llc
ManagerKen Griffin
Latest Disclosed Ownership6,855,120 shares
Ownership 2.80%
Citadel Advisors Llc ownership in ALLO / Allogene Therapeutics, Inc.

2026-05-15 - Citadel Advisors Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 6,855,120 shares of Allogene Therapeutics, Inc. (US:ALLO). This represents 2.8 percent ownership of the company. In their previous filing dated 2025-07-16 , Citadel Advisors Llc had reported owning 13,346,151 shares, indicating a decrease of -48.64 percent.

Citadel Advisors Llc has a history of taking positions in derivatives of the underlying security (ALLO) in the form of stock options. The firm currently holds call options representing 61,500 of underlying shares valued at $150,060 USD and put options representing 32,000 of underlying shares valued at $78,080 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date
Effective
Date
Form Prev
Shares
Latest
Shares
ΔShares
(Percent)
Ownership
(Percent)
ΔOwnership
(Percent)
2026-05-15 2026-05-15 13G/A 13,346,151 6,855,120 -48.64 2.80 -54.10
2025-07-16 2025-07-16 13G 13,346,151 6.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

ALLO / Allogene Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 6,793,620 -5,317,800 -43.91 16,576 -0.10 0.0027
2026-02-17 2025-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 12,111,420 -1,860,137 -13.31 16,593 -4.23 0.0025
2025-11-14 2025-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 13,971,557 3,718,951 36.27 17,325 49.54 0.0026
2025-08-14 2025-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 10,252,606 49,277 0.48 11,585 -22.23 0.0020
2025-05-15 2025-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 10,203,329 4,854,233 90.75 14,897 30.75 0.0028
2025-02-14 2024-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 5,349,096 309,502 6.14 11,394 -19.26 0.0020
2024-11-14 2024-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 5,039,594 2,593,091 105.99 14,111 147.54 0.0027
2024-08-14 2024-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 2,446,503 -666,722 -21.42 5,700 -59.04 0.0012
2024-05-15 2024-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 3,113,225 -940,001 -23.19 13,916 6.96 0.0027
2024-02-14 2023-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 4,053,226 -62,404 -1.52 13,011 -0.28 0.0026
2023-11-14 2023-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 4,115,630 -624,711 -13.18 13,047 -44.62 0.0028
2023-08-14 2023-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 4,740,341 391,838 9.01 23,559 9.67 0.0049
2023-05-15 2023-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 4,348,503 3,808,199 704.83 21,482 532.17 0.0047
2023-02-14 2022-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 540,304 -352,551 -39.49 3,399 -64.76 0.0008
2022-11-14 2022-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 892,855 811,492 997.37 9,643 940.24 0.0022
2022-08-15 2022-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 81,363 -2,534,748 -96.89 927 -96.11 0.0002
2022-05-16 2022-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 2,616,111 241,614 10.18 23,833 -32.73 0.0049
2022-02-14 2021-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 2,374,497 2,064,988 667.18 35,427 345.40 0.0072
2021-11-15 2021-09-30 13F ALLOGENE THERAPEUTICS Cmn 019770106 309,509 -101,301 -24.66 7,954 -25.76 0.0017
2021-08-16 2021-06-30 13F ALLOGENE THERAPEUTICS COM 019770106 410,810 379,323 1,204.70 10,714 863.49 0.0024
2021-05-21 2021-03-31 13F/A-1 ALLOGENE THERAPEUTICS COM 019770106 31,487 -272,366 -89.64 1,112 -85.50 0.0003
2021-05-17 2021-03-31 13F ALLOGENE THERAPEUTICS COM 019770106 31,487 -272,366 1,112 0.0003
2021-02-16 2020-12-31 13F ALLOGENE THERAPEUTICS COM 019770106 303,853 240,364 378.59 7,669 220.34 0.0020
2020-11-16 2020-09-30 13F ALLOGENE THERAPEUTICS COM 019770106 63,489 -33,851 -34.78 2,394 -42.58 0.0007
2020-08-14 2020-06-30 13F ALLOGENE THERAPEUTICS Cmn 019770106 97,340 42,054 76.07 4,169 288.18 0.0015
2020-05-15 2020-03-31 13F ALLOGENE THERAPEUTICS Cmn 019770106 55,286 -960 -1.71 1,074 -26.49 0.0005
2020-02-14 2019-12-31 13F ALLOGENE THERAPEUTICS Cmn 019770106 56,246 -295,648 -84.02 1,461 -84.77 0.0006
2019-11-14 2019-09-30 13F ALLOGENE THERAPEUTICS Cmn 019770106 351,894 -91,683 -20.67 9,591 -19.47 0.0045
2019-08-14 2019-06-30 13F ALLOGENE THERAPEUTICS Cmn 019770106 443,577 -220,926 -33.25 11,910 -38.00 0.0055
2019-05-15 2019-03-31 13F ALLOGENE THERAPEUTICS Cmn 019770106 664,503 293,885 79.30 19,211 92.48 0.0096
2019-02-14 2018-12-31 13F ALLOGENE THERAPEUTICS Cmn 019770106 370,618 370,618 9,981 0.0055
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ALLOGENE THERAPEUTICS COM Call 61,500 -21.76 150 40.19 n/a n/a n/a
2026-02-17 2025-12-31 13F ALLOGENE THERAPEUTICS COM Call 78,600 195.49 108 234.38 n/a n/a n/a
2025-11-14 2025-09-30 13F ALLOGENE THERAPEUTICS COM Call 26,600 -63.06 33 -60.49 n/a n/a n/a
2025-08-14 2025-06-30 13F ALLOGENE THERAPEUTICS COM Call 72,000 -3.23 81 -25.00 n/a n/a n/a
2025-05-15 2025-03-31 13F ALLOGENE THERAPEUTICS COM Call 74,400 31.22 109 -10.00 n/a n/a n/a
2025-02-14 2024-12-31 13F ALLOGENE THERAPEUTICS COM Call 56,700 950.00 121 700.00 n/a n/a n/a
2024-11-14 2024-09-30 13F ALLOGENE THERAPEUTICS COM Call 5,400 -60.58 15 -51.61 n/a n/a n/a
2024-08-14 2024-06-30 13F ALLOGENE THERAPEUTICS COM Call 13,700 407.41 32 158.33 n/a n/a n/a
2024-05-15 2024-03-31 13F ALLOGENE THERAPEUTICS COM Call 2,700 -70.33 12 -58.62 n/a n/a n/a
2024-02-14 2023-12-31 13F ALLOGENE THERAPEUTICS COM Call 9,100 54.24 29 61.11 n/a n/a n/a
2023-11-14 2023-09-30 13F ALLOGENE THERAPEUTICS COM Call 5,900 -59.86 19 -75.34 n/a n/a n/a
2023-08-14 2023-06-30 13F ALLOGENE THERAPEUTICS COM Call 14,700 -28.29 73 -27.72 n/a n/a n/a
2023-05-15 2023-03-31 13F ALLOGENE THERAPEUTICS COM Call 20,500 41.38 101 10.99 n/a n/a n/a
2023-02-14 2022-12-31 13F ALLOGENE THERAPEUTICS COM Call 14,500 -40.33 91 -65.27 n/a n/a n/a
2022-11-14 2022-09-30 13F ALLOGENE THERAPEUTICS COM Call 24,300 4.74 262 -0.76 n/a n/a n/a
2022-08-15 2022-06-30 13F ALLOGENE THERAPEUTICS COM Call 23,200 -19.72 264 0.38 n/a n/a n/a
2022-05-16 2022-03-31 13F ALLOGENE THERAPEUTICS COM Call 28,900 -31.84 263 -58.45 n/a n/a n/a
2022-02-14 2021-12-31 13F ALLOGENE THERAPEUTICS COM Call 42,400 61.22 633 -6.36 n/a n/a n/a
2021-11-15 2021-09-30 13F ALLOGENE THERAPEUTICS Cmn Call 26,300 80.14 676 77.43 n/a n/a n/a
2021-08-16 2021-06-30 13F ALLOGENE THERAPEUTICS COM Call 14,600 5.04 381 -22.40 n/a n/a n/a
2021-05-21 2021-03-31 13F/A ALLOGENE THERAPEUTICS COM Call 13,900 -15.76 491 18.03 n/a n/a n/a
2021-05-17 2021-03-31 13F ALLOGENE THERAPEUTICS COM Call 13,900 491 n/a n/a n/a
2021-02-16 2020-12-31 13F ALLOGENE THERAPEUTICS COM Call 16,500 -12.70 416 -41.65 n/a n/a n/a
2020-11-16 2020-09-30 13F ALLOGENE THERAPEUTICS COM Call 18,900 -32.50 713 -40.53 n/a n/a n/a
2020-08-14 2020-06-30 13F ALLOGENE THERAPEUTICS Cmn Call 28,000 59.09 1,199 250.58 n/a n/a n/a
2020-05-15 2020-03-31 13F ALLOGENE THERAPEUTICS Cmn Call 17,600 40.80 342 5.23 n/a n/a n/a
2020-02-14 2019-12-31 13F ALLOGENE THERAPEUTICS Cmn Call 12,500 45.35 325 38.89 n/a n/a n/a
2019-11-14 2019-09-30 13F ALLOGENE THERAPEUTICS Cmn Call 8,600 -37.23 234 -36.41 n/a n/a n/a
2019-08-14 2019-06-30 13F ALLOGENE THERAPEUTICS Cmn Call 13,700 -29.74 368 -34.75 n/a n/a n/a
2019-05-15 2019-03-31 13F ALLOGENE THERAPEUTICS Cmn Call 19,500 8.94 564 17.01 n/a n/a n/a
2019-02-14 2018-12-31 13F ALLOGENE THERAPEUTICS Cmn Call 17,900 482 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F ALLOGENE THERAPEUTICS COM Put 32,000 70.21 78 212.00 n/a n/a n/a
2026-02-17 2025-12-31 13F ALLOGENE THERAPEUTICS COM Put 18,800 -8.74 26 0.00 n/a n/a n/a
2025-11-14 2025-09-30 13F ALLOGENE THERAPEUTICS COM Put 20,600 -0.48 26 8.70 n/a n/a n/a
2025-08-14 2025-06-30 13F ALLOGENE THERAPEUTICS COM Put 20,700 -16.87 23 -36.11 n/a n/a n/a
2025-05-15 2025-03-31 13F ALLOGENE THERAPEUTICS COM Put 24,900 67.11 36 16.13 n/a n/a n/a
2025-02-14 2024-12-31 13F ALLOGENE THERAPEUTICS COM Put 14,900 -62.66 32 -72.07 n/a n/a n/a
2024-11-14 2024-09-30 13F ALLOGENE THERAPEUTICS COM Put 39,900 -5.90 112 13.27 n/a n/a n/a
2024-08-14 2024-06-30 13F ALLOGENE THERAPEUTICS COM Put 42,400 184.56 99 48.48 n/a n/a n/a
2024-05-15 2024-03-31 13F ALLOGENE THERAPEUTICS COM Put 14,900 -65.59 67 -52.17 n/a n/a n/a
2024-02-14 2023-12-31 13F ALLOGENE THERAPEUTICS COM Put 43,300 3.84 139 4.55 n/a n/a n/a
2023-11-14 2023-09-30 13F ALLOGENE THERAPEUTICS COM Put 41,700 23.74 132 -20.96 n/a n/a n/a
2023-08-14 2023-06-30 13F ALLOGENE THERAPEUTICS COM Put 33,700 31.64 167 32.54 n/a n/a n/a
2023-05-15 2023-03-31 13F ALLOGENE THERAPEUTICS COM Put 25,600 56.10 126 22.33 n/a n/a n/a
2023-02-14 2022-12-31 13F ALLOGENE THERAPEUTICS COM Put 16,400 -7.87 103 -46.35 n/a n/a n/a
2022-11-14 2022-09-30 13F ALLOGENE THERAPEUTICS COM Put 17,800 192 n/a n/a n/a
2022-08-15 2022-06-30 13F ALLOGENE THERAPEUTICS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-05-16 2022-03-31 13F ALLOGENE THERAPEUTICS COM Put 19,800 -35.50 180 -60.70 n/a n/a n/a
2022-02-14 2021-12-31 13F ALLOGENE THERAPEUTICS COM Put 30,700 151.64 458 45.86 n/a n/a n/a
2021-11-15 2021-09-30 13F ALLOGENE THERAPEUTICS Cmn Put 12,200 -48.52 314 -49.19 n/a n/a n/a
2021-08-16 2021-06-30 13F ALLOGENE THERAPEUTICS COM Put 23,700 -40.75 618 -56.23 n/a n/a n/a
2021-05-21 2021-03-31 13F/A ALLOGENE THERAPEUTICS COM Put 40,000 8.99 1,412 52.48 n/a n/a n/a
2021-05-17 2021-03-31 13F ALLOGENE THERAPEUTICS COM Put 40,000 1,412 n/a n/a n/a
2021-02-16 2020-12-31 13F ALLOGENE THERAPEUTICS COM Put 36,700 326.74 926 185.80 n/a n/a n/a
2020-11-16 2020-09-30 13F ALLOGENE THERAPEUTICS COM Put 8,600 -53.76 324 -59.30 n/a n/a n/a
2020-08-14 2020-06-30 13F ALLOGENE THERAPEUTICS Cmn Put 18,600 -12.68 796 92.27 n/a n/a n/a
2020-05-15 2020-03-31 13F ALLOGENE THERAPEUTICS Cmn Put 21,300 159.76 414 94.37 n/a n/a n/a
2020-02-14 2019-12-31 13F ALLOGENE THERAPEUTICS Cmn Put 8,200 213 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.